



DAFTAR PUSTAKA

- Anestis, A Zoi I, Papavassiliou, AG. and Karamouzis, M.V 2020. Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights. *Molecules*. 25, 358; Available from: doi:10.3390/molecules25020358
- Angajala. A., Mothershed, E., Davis, M.B., Tripathi, S., He. Q., Bedi. D., Dean-Colomb .W. and Yates. C. 2019. Quadruple Negative Breast Cancers (QNBC) Demonstrate Subtype Consistency among Primary and Recurrent or Metastatic Breast Cancer. *Translational Oncology* 12, 493–501.
- Agrawal, A.K., Jeleñ, M., Grzebieniak, Z., Zukrowski, P., Rudnicki, J., Nienartowicz, E. 2008. Androgen receptors as a prognostic and predictive factor in breast cancer. *Folia Histochemica Et Cytobiologica* Vol. 46, No. 3, pp. 269-276
- Asano, Y., Kashiwagi, S., Goto, W., Tanaka, S., Morisaki, T. *et al.* 2017 Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer. *Cancers*
- Astvatsaturyan K, Yue Y, Walts AE, Bose . 2018. Androgen Receptor Positive Triple Negative Breast Cancer: Clinicopathologic, Prognostic, and Predictive Features. *PlosOne*
- Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS *et al.*, 2015. Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo. *Molecular Cancer Therapeutics*. 14(3) March
- Barton VN, D'Amato NC, Gordon MA, Christenson JL, Elias A, Richer JK. 2015. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. *Horm Canc*. 6:206–213
- Bhattarai S, Klimov S, Mittal K, Krishnamurti U, Li X, Oprea-Ilies G, Wetherilt CS, Riaz A, Aleskandarany MA, Green AR, Ellis IO, Cantuaria G, Gupta, Manne U, *et al.* 2019. Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. *Cancers* 11,995
- Boyle P. 2012. Triple-negative breast cancer: epidemiological considerations and recommendations. *Annals of Oncology* 23 (Supplement 6): vi7–vi12
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018 Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality worldwide for 36 Cancers in 185 Countries. *Ca Cancer J Clin* 68:394–424
- Brewster A. Mac Gregor MC & Brown. 2012. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. *Lancet Oncol*.
- Carey L, Perou CM. Livasy CA, Dressler LG, Cowan D *et al.* 2006. Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. *JAMA*, June 7—Vol 295, No. 21



- Chavez KJ, Garimella SV, & Lipkowitz S. 2010. Triple Negative Breast Cancer Cell Lines: One Tool in the Search for Better Treatment of Triple Negative Breast Cancer. *Breast Disease*; 32(1-2): 35–48.
- Choi J, Psarommatis B, Gao YR, Zheng Y, Handelsman DJ. 2014. The role of Androgens in experimental rodent mammary carcinogenesis. *Breast Cancer Research* 2014, 16:483
- Cochrane DR, Bernales S, Jacobsen BM. 2014. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. *Breast Cancer Research* 2014, 16:R7
- Clark TG, Bradburn MJ, Love SB and Altman DG. 2003. Survival Analysis Part I: Basic concepts and first analyses. Tutorial paper. *British Journal of Cancer* 89, 232 – 238
- Datta G, Alexander LE, Hinterberg MA, and Hagar Y. 2019. Balanced Event Prediction Through Sampled Survival Analysis. Machine Learning Special Issue. *Systems Medicine* Volume 2.1, 2019 DOI: 10.1089/sysm.2018.0015
- Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK *et al.*, 2007. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence *Clin Cancer Res* 13(15)
- Dieci MV, Tsvetkova V, Griguolo G, Miglietta F, Mantiero M, Tasca G, Cumerlato E, Giorgi CA, Giarratano T, Faggioni G, Falci C, Vernaci G, Menichetti A, Mioranza E, Di Liso E, Frezzini S, Saibene T, Orvieto E and Guarneri V. 2019. Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease. *Frontiers in Oncology*. Vol 9. Article 452
- Elebro K, Borgquist S, Simonsson M, Markkula A, Jirström K, Ingvar C, Rose C, Jernström H. 2015. Combined androgen and estrogen receptor status in breast cancer: Treatment prediction and prognosis in a population-based prospective cohort. *Clin. Cancer Res.* **2015**, *21*, 3640–3650.
- Fragomeni SM, Sciallis A & Jeruss JS, 2018. Molecular subtypes and local-regional control of breast cancer. *Surg Oncol Clin N Am.* 27(1): 95–120
- Garay JP, Park BH. 2012. Androgen receptor as a targeted therapy for breast Cancer Review Article *Am J Cancer Res* ;2(4):434-445
- Gasparini P, Fassan M, Cascione L, Guler G, *et al.*, 2014. Androgen Receptor Status Is a Prognostic Marker in NonBasal Triple Negative Breast Cancers and Determines Novel Therapeutic Options. Androgen Receptor in Breast Cancer. *PlosOne*. February 2014 | Volume 9 | Issue 2 | e88525
- Giannos A, Filipits M, Zagouri F, Brandstetter A, Tsigginou A, Sotiropoulou A, Papaspyrou I, Sergentanis T, Psaltopoulou T, Rodolakis A, Antsaklis A, Dimopoulos M, Dimitrakakis C, 2015. Expression of ARs in Triple Negative Breast Cancer Tumors: a Potential Prognostic Factor? *OncoTargets and Therapy* 2015;8 1843–1847



- Gerratanaa L, Basilea D, Buonob G, De Placidob S, Giulianob M, Minichilloc S, Coinud A. *et al*, 2018. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. *Cancer Treatment Reviews* 68. 102-110. *Elsevier*
- Global Cancer Facts & Figures 4th Edition, 2018 Estimated Number of New Cancer Cases by World Area,. *Globocan*.
- Graham TR, Yacoub R, Taliaferro-Smith LT Osunkoya AO, Odero-Marah VA et al. 2010. Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. *Breast Cancer Res Treat*. August ; 123(1): 139–147
- Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K et al., , 2013 Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer. *Clin Cancer Res*. October 1; 19(19): 5505–5512
- Hoyle, R. 2018. Chapter 7. Analysis Techniques for Small Population Research. In Nancy Kirkendall and Jordyn White (Rapporteurs). Improving Health Research on Small Populations. Proceedings of A Workshop. *The National Academies Press*.
- Hubalek, Czech T, Czech, 2017. Biological Subtypes of Triple-Negative Breast Cancer. *Breast Care*;12:8–14
- Kim S, Moon BI, Lim W, Park S, Cho MS, Sung SH. 2016. Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer. *Human Pathology* 55, 190–195
- Kumar V, Yu J, V Phan, Tudor JC, Peterson A, Uppal H, 2017. Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer. *ascopubs.org/journal/po*. JCO™ Precision Oncology
- Lacopetta D, Rechoum Y, Fuqua SAW, 2012. The Role of Androgen Receptor in Breast Cancer. *Drug Discov Today Dis Mech*. 9(1-2): e19–e27
- Lacroix-Triki M, 2020. New Breast Cancer Classification: Traditional Pathology and Molecular Subtype. *ESMO Breast Cancer Preceptorship*, Cape Town South Africa Feb.
- Lehman BD, Shyr Y, Pietenpol JA. 2011. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest*. 121(7):2750-2767.
- Lehmann BD, Jovanović B, Xi Chen, Estrada MV, Johnson KN, Yu Shyr, Moses HL, Sanders ME, Pietenpol JA. 2016. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. *Plos One*.
- Makki J, 2015. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. *Clinical Medicine Insights: Pathology* 2015:8
- Marmé F, Schneeweiss A. 2015. Targeted Therapies in Triple-Negative Breast Cancer. *Breast Care* 2015;10:159–166
- McGhan LJ, McCullough AE, Protheroe CA, Dueck AC, Lee JJ *et al.*, 2013. Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype. *Ann Surg Oncol*
- Mina A, Yoder R, Sharma P. 2017. Targeting the androgen receptor in triple-negative breast cancer: current perspectives. *OncoTargets and Therapy* 10 4675–4685



- O'Brien K, Cole SR, Tse CK, Perou CM, Carey LA et al, 2010., Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study. *Clin Cancer Res*
- Ovcaricek T, Frkovic G, Matos E, Mozina B, Borstnar S. 2011. Triple negative breast cancer – prognostic factors and survival. *Radiol Oncol* 45(1): 46-52.
- Okoye JO & Okoye FP. 2015. MiRNA and Target Oncogene Regulation in Triple Negative Breast Cancer: An Age, Ethnic and Environmental Related Neoplastic Event. *Journal of Cancer and Tumor International*
- Quintario C, Zenzola V, Arguelles M and Pérez-Fernández E, 2019. Androgen Receptor as Prognostic Marker in Triple-Negative Breast Cancer Patients. *J. Med Surg Pathol*
- Rahim B & O'Regan R, 2017. AR Signaling in Breast Cancer. *Cancers*. MDPI
- Rampurwala M, Wisinski KB and O'Regan R. 2016. Role of the Androgen Receptor in Triple-Negative Breast Cancer. *Clinical Advances in Hematology & Oncology* Volume 14, Issue 3 March
- Reddy GM, Suresh PK, Pai RR. 2017. Clinicopathological Features of Triple Negative Breast Carcinoma. *Journal of Clinical and Diagnostic Research*. Jan, Vol-11(1): EC05-EC08
- Ricciardelli C, Bianco-Miotto T, Shalini, Butler JLM, Leung S, McNeil CM, et al. 2018. The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. *Clin Cancer Res*; 24(10) May 15
- Sasahara M, Matsui A, Ichimura Y, Hirakatai Y, Murata Y, Marui E, Overexpression of Androgen Receptor and Forkhead-box A1 Protein in Apocrine Breast Carcinoma. *Anticancer Research* 34: 1261-1268
- Secreto G, Zumoff B. 2012. Role of Androgen Excess in the Development of Estrogen Receptor-positive and Estrogen Receptor-negative Breast Cancer *Anticancer Research* 32: 3223-3228
- Solikhah S, Promthet S, Rakkapao N, Hurst CP. 2017. Validation of an Indonesian Version of the Breast Cancer Awareness Scale (BCAS-I). *Asian Pac J Cancer Prev*, 18 (2), 515-522
- Stephanie, 2014. Cohen's Kappa Statistic. *Statistic How To* ©2020
- Sung Gwe Ahn, Seung Jun Kim¹, Cheungyeul Kim², Joon Jeong 2016. Molecular Classification of Triple-Negative Breast Cancer. *J Breast Cancer September*; 19(3): 223-230
- Shah PD, Gucalp A, Traina TA. 2013. The role of the androgen receptor in triple-negative breast cancer. *Women's Health* 9(4)
- Sporikova Z, Koudelakova V, Trojanec R, Hajduch M. 2018. Genetic Markers in Triple-Negative Breast Cancer. *Clinical Breast Cancer*, Vol. 18, No. 5, e841-50
- Tesarova P. 2016. Review Article Specific Aspects of Breast Cancer Therapy of Elderly Women. Review Article. *BioMed Research International* Volume Article ID 1381695, 8 pages



- Sastroasmoro, S dan Ismael, S. 2011. Dasar-dasar Metodologi Penelitian Klinis. *Binarupa Aksara*
- Urru, Gallus Y, Cri Maria Cristina Bosetti, Tiziana Moi, Medda *et al.* 2018. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. *BMC Cancer*
- Uva P, Cossu-Rocca P, Loi F, Pira G, Murgia F, Orrù S, Floris M *et al.* 2018. miRNA-135b Contributes to Triple Negative Breast Cancer Molecular Heterogeneity: Different Expression Profile in Basal-like Versus non-Basal-like Phenotypes. *Int. J. Med. Sci.* 2018, Vol. 15
- Wang Y, Romigh T, He X, Tan MH, Orloff MS, Silverman RH, Heston WD & Eng C. 2011. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. *Oncogene* 30, 4327–4338
- Wang C, Hanjiang W Yidong *et al.*, 2018. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis, *Oncotarget*, Vol 7 No. 29.
- Wu Y. & Vadgama JV, 2017. Androgen Receptor as a Potential Target for Treatment of Breast Cancer. *Int J Cancer Res Mol Mech.*
- Xu, M, Yuan Y, Yan P, Jiang J, Ma P, Niu X, Ma S, Cai H, Yang K. 2020. Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis. Review. *Clinical Breast Cancer*
- Yadav BS, Chanana P, Jhamb S. 2015. Biomarkers in triple negative breast cancer: A review. *World Journal of Clinical Oncology* December 10; 6(6): 252-263
- Yu Q, Niu Y, Liu N, Zhang JZ, Liu TJ, Zhang RJ, Wang SL, Ding XM & Xiao XQ. 2010. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. *Annals of Oncology* 22: 1288–1294, 2011
- Zakaria F, El-Mashad L, Mohamed D. 2015. Androgen receptor expression as a prognostic and predictive marker in triple-negative breast cancer patients. Original article, *Alexandria Journal of Medicine* 52, 131–140
- Zhao Y, Tindall DJ, Huang H. 2014. Modulation of Androgen Receptor by FOXA1 and FOXO1 Factors in Prostate Cancer International Journal of Biological Sciences 10(6): 614-619. *Ivispring International Publisher*
- Zuo T, Wilson P, Cicek AF, Harigopal M, 2018. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers. *Human Pathology* 80, 239–245